Novartis to get rights to HCV compound
Novartis has agreed to pay privately-owned Enanta Pharmaceuticals Inc $34 million upfront, plus potential milestones of $406 million, for exclusive rights to a compound to treat hepatitis C. The compound is poised to enter clinical development.